STOCKS TELEGRAPH

Tag: DBVT

  • Participation at Healthcare Conference: DBV Technologies S.A. (DBVT) Stock Recovered in Tuesday’s Premarket.

    Participation at Healthcare Conference: DBV Technologies S.A. (DBVT) Stock Recovered in Tuesday’s Premarket.

    DBV Technologies S.A. (DBVT) is producing an exclusive technology platform known as Viaskin, having a wide range of applications in immunotherapeutics and based on EPIT. It belongs to a new class of non-invasive candidate products. The safe transformation of food allergic patients’ care is the goal of the company.

    DBVT stock price during the regular trading on March 14, 2022, declined 1.45% to be $1.36. Its price soared by 5.15% at the last check of the premarket session of March 15, 2022.

    DBVT: Events and Happenings

    On March 14, 2022, DBVT reported its CMO will present at the Oppenheimer’s 32nd Annual Healthcare Conference was held on March 17, 2022.

    DBVT: Key Financials

    DBVT released its full fiscal year 2021 financials on March 3, 2022, for the year ended December 31, 2021. Some significant features are shared here.

    Revenue

    Revenues in fiscal 2021 were $5.7 million against $11.2 million in fiscal 2020. The company observed an increase of $5.56 million in its revenue YoY.

    EPS

    FY 2021 net loss basic and diluted per share was $97.8 million or $1.78 compared to $159.5 million or $2.95 for the comparable year 2020. The company’s EPS nose-dived YoY. Also, its EPS remained in line with the expectations.

    On February 22, 2022, DBVT updated on the participation of its management at the Annual Scientific Meeting of the American Academy of Allergy, Asthma, and Immunology on February 24-28. On February 14, 2022, DBVT announced the presentation of its CEO at the 11th Annual SVB Leerink Global Healthcare Conference on February 18. On January 21, 2022, DBVT issued its half-yearly statement of its liquidity agreement with ODDO BHF.

    Conclusion

    DBVT stock plunged deep in the last six months by 73%. Its current stock position is good as the company announced its Executive management’s participation at the Oppenheimer’s Healthcare Conference, hence its stock price surged in the premarket. For the first quarter of 2022, the company’s expectation of revenue is $1.28 million and -$0.40 EPS.

  • DBV Technologies S.A. (DBVT) stock plunged in the pre-market. Here’s why

    DBV Technologies S.A. (DBVT) stock plunged in the pre-market. Here’s why

    The stock of DBV Technologies S.A. (DBVT) lost 20.00% in the pre-market to $1.40 after releasing the fiscal performance for FY2021. DBVT stock closed the regular trading session at $1.75, gaining 34.62% from the previous day’s trading session. The stock kept moving between $1.44 and $1.75. DBV Technologies also filed form 8-K with the SEC on 3 March 2022.

    DBV Technologies SA is a biopharmaceutical firm known for creating “Viaskin” innovation. It regulates the allergens or antigens to unblemished skin while keeping away from any movement to the blood. The company has a market cap of $96.14 million with 54.94 million pending shares. DBVT has its headquarter in Mont rouge, France.

    DBVT’s key financials

    On 3 March 2022, DBV Technologies released the fiscal performance for FY2021. The firm’s sales for FY21 reduced by 49.3% to $5.7 million in 2021 from $11.2 million in 2020. DBVT had the expense from the operation of $104.3 million in 2021 versus $170.1 million in 2020. This marks a contraction of 38.6% in the expenses from operations. Moreover, the firm reported a total loss of $97.8 million in 2021 against $159.5 million in 2020. The total loss declined by 38.6%. Also, the loss of $1.78 per stock in 2021 is compared to the loss of $2.95 per stock in 2020. The loss per stock also declined by 39.6%. Moreover, as of December 31, 2021, DBVT had total assets worth $146.7 million of which cash and cash equivalents were $77.3 million.

    CEO Remarks

    The CEO of DBVT, Daniel Tasse, commented that starting the new Phase 3 preliminary with the mVP is their main concern. They are satisfied with the continuous discussions with FDA. He further added that they expect this financial position will give DBV an adequate chance to acquire an alliance with FDA on the convention for the mVP essential preliminary.

    Further, Mr. Tasse concluded that they expect to understand the maximum capacity of the Viaskin innovation for patients and families.

  • DBV Technologies S.A. (DBVT) stock making a comeback after heavy losses

    DBV Technologies S.A. (DBVT) stock rallied by 23.74% at $1.72 premarket, at the last check on Wednesday. The stock is making gains after experiencing a sharp selloff on news that The Viaskin Peanut patch will have to undergo another costly phase 3 trial before it has a realistic chance of being approved by the FDA. For the same reason, it has also withdrawn an application pending with the European Medicines Agency.

    In the previous trading session, the stock saw huge losses, as it slid down to a 52-week low of $1.3510. DBVT closed the session at $1.39 with a loss of 48.52% at 15.4 million shares. At the time of writing the stock was up by $0.32 at a premarket volume of 623.7K shares.

    Currently, the clinical-stage biopharmaceutical company DBV Technologies S.A. has a market capitalization of $304.01 million.

    What is happening?

    On December 20, the company announced the initiation of a new phase 3 trial of its modified Viaskin Peanut patch. The announcement caused the stock to decline to its new 52-week low. The reason for the new trial being taken so negatively was the history of the trial itself. Previously, FDA had refused to approve the Viaskin Peanut patch due to adhesion problems. While DBVT modified the patch, it did not feel the need for a new phase 3 trial. Finally, the company admitted the need for a new phase 3 trial in order to receive approval from the FDA.

    DBVT’s Investigational ViaskinTM Peanut

    Viaskin Peanut is the company’s investigational product for peanut allergies in the different age groups of people including kids under 3.

    According to the updates provided by the company on December 20, the modified Viaskin Peanut (mVP) patch is circular in shape and is almost 50% larger than the current one. Moreover, the new phase 3 study of the patch will also add updates to its IFU (Instructions for Use).

    Furthermore, at the end of November, FDA had requested DBVT for further information regarding the allergen uptake/transport comparability of the mVP to the current patch. Hence, the company intends to continue communicating with the FDA before initiating the allergen uptake comparison.

    DBVT’s Financial Highlights

    On October 26, the company declared its third-quarter financial results for 2021. In the Q3 of 2021, DBVT incurred a net loss of $24.0 million or $0.44 per share.

    Moreover, the company ended the quarter with cash and equivalents of $98.2 million.

  • Early Morning Vibes: Top 4 Stocks To Watch Right Now

    Early Morning Vibes: Top 4 Stocks To Watch Right Now

    For Martin Luther King Day, the U.S. treasuries were closed yesterday. In the meantime, on Wednesday, the Americans are waiting for the unveiling of Joe Biden. In the run-up to that time, a $1900 billion corona support plan was already revealed. Janet Yellen, Minister of Economy, also accepts. The former Fed Chairman suggests that a massive boost can be used to generate the existing low-interest rates.

    The future of New York is now pointed to a higher start. The S&P future is 0.48% higher and the Nasdaq trading is even 0.80% higher. The annual findings of Bank of America and Goldman Sachs will be revealed this afternoon at 1 p.m. It’s the turn of Netflix after the closure at 10:00 PM. In the fourth quarter of 2020, JPMorgan Chase analysts plan to welcome 6 million users on the subscription site.

    Today Top Movers

    DBV Technologies (DBVT), a biotechnology company, rose about 37.99% ‎at $7.81 in pre-market trading Tuesday after it declared the receipts of written responses from the FDA to the question asked for the ‎Type A request the company submitted in Oct 2020.

    Gevo Inc (GEVO) share price climbed 39.22% to $8.91 during early morning ‎trading session on Tuesday.‎ The company will participate in Water Tower Research Fireside Chat Series on Thursday, January 21, 2021 at 3:00 pm EST.

    Nio Inc (NIO) stock escalated 4.37% at $58.73 in the pre-‎market trading today after declaring the closing of US$1.5 billion convertible senior notes.

    Castor Maritime Inc (CTRM) hiked over 8.10% at $0.36 in pre-market ‎trading on Tuesday.‎

    Top Upgrades & Downgrades

    KeyBanc turned bullish on Facebook Inc. (FB), upgrading the stock to “Overweight” and assigning a $345.0 price target, representing a potential upside of 29.3% from Friday’s close.

    Darden Restaurants Inc. (DRI) has won the favor of Morgan Stanley’s equity research team. The firm upgraded the shares from Equal-Weight to Overweight and moved their price target to $142.0, suggesting 17.23% additional upside for the stock. 

    Arch Capital Group Ltd. (ACGL) received an upgrade from analysts at JMP Securities. They changed their rating on ACGL to Market Outperform from Market Perform in a recently issued research note. 

    Earlier Tuesday BofA reduced its rating on Acadia Realty Trust (NYSE: AKR) stock to Neutral from Buy and assigned the price target to $17.50. 

    BofA analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Premier Inc (NASDAQ: PINC) has been changed to Underperform from Buy and the new price target is set at $36. 

    Analysts at BofA downgraded Cerner Corporation (NASDAQ: CERN)’s stock to Underperform from Buy Tuesday.

    Latest Insider Activity

    TransEnterix Inc. (TRXC) Director Milne David Bruce announced the sale of shares taking place on Jan 15 at $2.10 for some 147,058 shares. The total came to more than $0.31 million.

    Inovio Pharmaceuticals Inc. (INO) CFO KIES PETER sold on Jan 15 a total of 119,290 shares at $10.02 on average. The insider’s sale generated proceeds of almost $0.3 million. 

    Amicus Therapeutics Inc. (FOLD) Director WHITMAN BURKE W declared the purchase of shares taking place on Jan 04 at $23.17 for some 1,500 shares. The transaction amount was around $34755. 

    C.H. Robinson Worldwide Inc. (CHRW) Director SHORT BRIAN bought on Jan 04 a total 21,843 shares at $93.58 on average. The purchase cost the insider an estimated $5,159.

    Important Earnings

    Top US earnings releases scheduled for today include Bank of America Corporation (NYSE: BAC). It will announce its Dec 2020 financial results. The company is expected to report earnings of $0.55 per share from revenues of $20.68B in the three-month period.

    Analysts expect Halliburton Company (NYSE: HAL) to report a net income (adjusted) of $0.15 per share when the bank releases its quarterly results shortly. Revenue for the fiscal quarter ended Dec 2020 is predicted to come in at $3.21B.

    Netflix Inc. (NFLX), due to announce earnings after the market closes today, is expected to report earnings of $1.39 per share from revenues of $6.63B recently concluded three-month period.